AU2015292956B2 - Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof - Google Patents

Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof Download PDF

Info

Publication number
AU2015292956B2
AU2015292956B2 AU2015292956A AU2015292956A AU2015292956B2 AU 2015292956 B2 AU2015292956 B2 AU 2015292956B2 AU 2015292956 A AU2015292956 A AU 2015292956A AU 2015292956 A AU2015292956 A AU 2015292956A AU 2015292956 B2 AU2015292956 B2 AU 2015292956B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
cytosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015292956A
Other languages
English (en)
Other versions
AU2015292956A1 (en
Inventor
Dong Ki Choi
Sung Hoon Kim
Yong Sung Kim
Seung Min Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orum Therapeutics Inc
Original Assignee
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc filed Critical Orum Therapeutics Inc
Priority claimed from PCT/KR2015/007627 external-priority patent/WO2016013871A1/ko
Publication of AU2015292956A1 publication Critical patent/AU2015292956A1/en
Application granted granted Critical
Publication of AU2015292956B2 publication Critical patent/AU2015292956B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobodyยฎ
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015292956A 2014-07-22 2015-07-22 Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof Ceased AU2015292956B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20140092687 2014-07-22
KR10-2014-0092687 2014-07-22
KR1020150103214A KR101602876B1 (ko) 2014-07-22 2015-07-21 ์™„์ „ํ•œ ์ด๋ฎค๋…ธ๊ธ€๋กœ๋ถˆ๋ฆฐ ํ˜•ํƒœ์˜ ์„ธํฌ์งˆ ์นจํˆฌ๋Šฅ์„ ๊ฐ–๋Š” ํ•ญ์ฒด๋ฅผ ์ด์šฉํ•˜์—ฌ ์„ธํฌ๋‚ด ํ™œ์„ฑํ™”๋œ ras๋ฅผ ์–ต์ œํ•˜๋Š” ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์ด์šฉ
KR10-2015-0103214 2015-07-21
PCT/KR2015/007627 WO2016013871A1 (ko) 2014-07-22 2015-07-22 ์™„์ „ํ•œ ์ด๋ฎค๋…ธ๊ธ€๋กœ๋ถˆ๋ฆฐ ํ˜•ํƒœ์˜ ์„ธํฌ์งˆ ์นจํˆฌ๋Šฅ์„ ๊ฐ–๋Š” ํ•ญ์ฒด๋ฅผ ์ด์šฉํ•˜์—ฌ ์„ธํฌ๋‚ด ํ™œ์„ฑํ™”๋œ ras๋ฅผ ์–ต์ œํ•˜๋Š” ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์ด์šฉ

Publications (2)

Publication Number Publication Date
AU2015292956A1 AU2015292956A1 (en) 2017-02-09
AU2015292956B2 true AU2015292956B2 (en) 2020-04-02

Family

ID=55354089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015292956A Ceased AU2015292956B2 (en) 2014-07-22 2015-07-22 Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof

Country Status (11)

Country Link
US (1) US10851177B2 (enExample)
EP (1) EP3173099B1 (enExample)
JP (1) JP6798988B2 (enExample)
KR (2) KR101602876B1 (enExample)
CN (1) CN106999575A (enExample)
AU (1) AU2015292956B2 (enExample)
BR (1) BR112017001306A2 (enExample)
CA (1) CA2955265A1 (enExample)
IL (1) IL250137B (enExample)
MX (1) MX2017001012A (enExample)
RU (1) RU2017103679A (enExample)

Families Citing this family (11)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602870B1 (ko) 2014-07-22 2016-03-21 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์™„์ „ํ•œ ์ด๋ฎค๋…ธ๊ธ€๋กœ๋ถˆ๋ฆฐ ํ˜•ํƒœ์˜ ํ•ญ์ฒด๋ฅผ ์„ธํฌ๋ง‰์„ ํˆฌ๊ณผํ•˜์—ฌ ์„ธํฌ์งˆ์— ์œ„์น˜์‹œํ‚ค๋Š” ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์ด์šฉ
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
EP3712180A4 (en) * 2017-11-16 2021-08-11 Orum Therapeutics Inc. ANTIBODIES WITH INHIBITION OF ACTIVATED RAS IN A CELL BY INTERNALIZATION IN A CYTOSOL OF THE CELL AND ITS USE
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
US20210292409A1 (en) * 2018-07-23 2021-09-23 Chugai Seiyaku Kabushiki Kaisha Target cell specific cytosol-penetrating antigen-binding molecules
WO2020149613A1 (ko) * 2019-01-15 2020-07-23 ์˜ค๋ฆ„ํ…Œ๋ผํ“จํ‹ฑ ์ฃผ์‹ํšŒ์‚ฌ ์„ธํฌ์งˆ ์นจํˆฌ์„ฑ์ด ์ฆ์ง„๋œ ํ•ญ์ฒด
AU2020266770A1 (en) * 2019-05-01 2021-10-14 Universidade De Santiago De Compostela Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules
WO2021222333A1 (en) * 2020-04-30 2021-11-04 Genentech, Inc. Kras specific antibodies and uses thereof
MX2023011608A (es) * 2021-04-02 2023-12-14 Massachusetts Gen Hospital Metodos para inhibir ras.
EP4375294A1 (en) 2021-07-20 2024-05-29 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating degrading antibody that penetrates into cells to degrade and remove target protein and use thereof
US20250122308A1 (en) * 2021-09-17 2025-04-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeting mutant kras with a mutation specific iga

Citations (5)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
US20050288492A1 (en) * 2002-11-15 2005-12-29 Medical Research Council Anti-activated RAS antibodies
KR20100045683A (ko) * 2008-10-24 2010-05-04 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ํ•ต์‚ฐ๊ฐ€์ˆ˜๋ถ„ํ•ด ๋Šฅ ๋ฐ ์•”์„ธํฌ๋‚ด ์นจํˆฌ๋Šฅ๋ ฅ์„ ๊ฐ–๋Š” ์ธ๊ฐ„ํ™”๋œ ํ•ญ์ฒด ๋ฐ ๊ทธ ์šฉ๋„
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
US20140179543A1 (en) * 2011-03-03 2014-06-26 Isis Innovation Limited Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction

Family Cites Families (22)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Sรฉquences nuclรฉiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thรฉrapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 ไธญๅ›ฝไบบๆฐ‘่งฃๆ”พๅ†›็ฌฌๅ››ๅ†›ๅŒปๅคงๅญฆ ๆŠ—่‚็™Œๅ•ๅ…‹้š†ๆŠ—ไฝ“HAb25ๅŠๅ…ถๅ•้“พๆŠ—ไฝ“ๅ’ŒๅŒๅŠŸ่ƒฝๆŠ—ไฝ“
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaร‡รงo ras e composiร‡ร•es e mร‰todos de uso da mesma
KR101658247B1 (ko) 2008-01-03 2016-09-22 ๋” ์Šคํฌ๋ฆฝ์Šค ๋ฆฌ์„œ์น˜ ์ธ์Šคํ‹ฐํŠœํŠธ ๋ชจ๋“ˆ ์ธ์‹ ๋„๋ฉ”์ธ์„ ํ†ตํ•œ ํ•ญ์ฒด ํ‘œ์ ํ™”
KR100849941B1 (ko) 2008-04-29 2008-08-01 ์›์šฐ์ด์—ํ”„์—”์ง€๋‹ˆ์–ด๋ง์ฃผ์‹ํšŒ์‚ฌ ์—ด ๋ฐ ์—ฐ๊ธฐ ํ™”์žฌ๊ฐ์ง€์žฅ์น˜ ๋ณตํ•ฉ์‹œํ—˜๊ธฐ
US20110159569A1 (en) * 2008-04-30 2011-06-30 Ajou University IndustryAcademic Cooperation Found Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
CN101402675B (zh) * 2008-11-28 2012-05-30 ไธญๅ›ฝไบบๆฐ‘่งฃๆ”พๅ†›็ฌฌไธ‰ๅ†›ๅŒปๅคงๅญฆ็ฌฌไธ‰้™„ๅฑžๅŒป้™ข ไธ€็ง้ถๅ‘ๆŠ‘ๅˆถฮฑฮฝฮฒ3้˜ณๆ€ง็ป†่ƒžๅขžๆฎ–็š„็Žฏ่‚ฝ
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
JP6178785B2 (ja) * 2011-04-01 2017-08-09 ใ‚คใ‚งใƒผใƒซ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃใƒผ๏ผน๏ฝ๏ฝŒ๏ฝ… ๏ผต๏ฝŽ๏ฝ‰๏ฝ–๏ฝ…๏ฝ’๏ฝ“๏ฝ‰๏ฝ”๏ฝ™ ็ดฐ่ƒžๆตธ้€ๆ€งๆŠ—๏ฝ„๏ฝŽ๏ฝๆŠ—ไฝ“ใŠใ‚ˆใณ๏ฝ„๏ฝŽ๏ฝไฟฎๅพฉใ‚’้˜ปๅฎณใ™ใ‚‹ใŸใ‚ใฎใใฎไฝฟ็”จ
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
JP6246128B2 (ja) 2012-09-14 2017-12-13 ๅ…ฌ็›Š่ฒกๅ›ฃๆณ•ไบบใŒใ‚“็ ”็ฉถไผš ๏ผฅ๏ฝ๏ผฃ๏ผก๏ผญใซ็ตๅˆใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2016013870A1 (ko) 2014-07-22 2016-01-28 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์™„์ „ํ•œ ์ด๋ฎค๋…ธ๊ธ€๋กœ๋ถˆ๋ฆฐ ํ˜•ํƒœ์˜ ํ•ญ์ฒด๋ฅผ ์„ธํฌ๋ง‰์„ ํˆฌ๊ณผํ•˜์—ฌ ์„ธํฌ์งˆ์— ์œ„์น˜์‹œํ‚ค๋Š” ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์ด์šฉ
KR101602870B1 (ko) 2014-07-22 2016-03-21 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์™„์ „ํ•œ ์ด๋ฎค๋…ธ๊ธ€๋กœ๋ถˆ๋ฆฐ ํ˜•ํƒœ์˜ ํ•ญ์ฒด๋ฅผ ์„ธํฌ๋ง‰์„ ํˆฌ๊ณผํ•˜์—ฌ ์„ธํฌ์งˆ์— ์œ„์น˜์‹œํ‚ค๋Š” ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์ด์šฉ
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
KR101790669B1 (ko) 2015-10-14 2017-10-26 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ๊ฐœ์„ ๋œ ๋ถ„ํ•  ๋…น์ƒ‰ ํ˜•๊ด‘ ๋‹จ๋ฐฑ์งˆ ์ƒ๋ณด ์‹œ์Šคํ…œ ๋ฐ ์ด์˜ ์šฉ๋„
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
KR101836392B1 (ko) 2016-08-17 2018-03-08 ํ•œ๋ฆผ๋Œ€ํ•™๊ต ์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์‚ฌ์ดํด๋ฆญ ํŽฉํƒ€์ด๋“œ๋ฅผ ํฌํ•จํ•˜๋Š” ๋ฐฑ์‹  ์กฐ์„ฑ๋ฌผ, ์‚ฌ์ดํด๋ฆญ ํŽฉํƒ€์ด๋“œ์— ๋Œ€ํ•œ ํ•ญ์ฒด ๋˜๋Š” ์ด๋ฅผ ํฌํ•จํ•˜๋Š” ํ•ญ์•” ์กฐ์„ฑ๋ฌผ
EP3712180A4 (en) 2017-11-16 2021-08-11 Orum Therapeutics Inc. ANTIBODIES WITH INHIBITION OF ACTIVATED RAS IN A CELL BY INTERNALIZATION IN A CYTOSOL OF THE CELL AND ITS USE
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies

Patent Citations (5)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
US20050288492A1 (en) * 2002-11-15 2005-12-29 Medical Research Council Anti-activated RAS antibodies
KR20100045683A (ko) * 2008-10-24 2010-05-04 ์•„์ฃผ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ํ•ต์‚ฐ๊ฐ€์ˆ˜๋ถ„ํ•ด ๋Šฅ ๋ฐ ์•”์„ธํฌ๋‚ด ์นจํˆฌ๋Šฅ๋ ฅ์„ ๊ฐ–๋Š” ์ธ๊ฐ„ํ™”๋œ ํ•ญ์ฒด ๋ฐ ๊ทธ ์šฉ๋„
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
US20140179543A1 (en) * 2011-03-03 2014-06-26 Isis Innovation Limited Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction

Non-Patent Citations (1)

* Cited by examiner, โ€  Cited by third party
Title
TANAKA, T. et al., "Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation", EMBO J., (2003), vol. 22, no. 5, pages 1025 - 1035 *

Also Published As

Publication number Publication date
CN106999575A (zh) 2017-08-01
RU2017103679A (ru) 2018-08-06
EP3173099A1 (en) 2017-05-31
EP3173099A4 (en) 2018-03-14
KR20160011599A (ko) 2016-02-01
BR112017001306A2 (pt) 2018-01-30
JP2017529870A (ja) 2017-10-12
US10851177B2 (en) 2020-12-01
MX2017001012A (es) 2018-06-19
EP3173099B1 (en) 2020-03-04
JP6798988B2 (ja) 2020-12-09
CA2955265A1 (en) 2016-01-28
IL250137A0 (en) 2017-03-30
IL250137B (en) 2020-05-31
KR101602876B1 (ko) 2016-03-11
KR101732553B1 (ko) 2017-05-08
KR20160033670A (ko) 2016-03-28
AU2015292956A1 (en) 2017-02-09
US20170158777A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
EP3173428B1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
AU2015292956B2 (en) Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
US20220041683A1 (en) Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused with Same, and Use Thereof
AU2017271189B2 (en) Cytosol-penetrating antibody and use thereof
KR102163305B1 (ko) ์„ธํฌ์˜ ์„ธํฌ์งˆ์— ์นจํˆฌํ•˜์—ฌ ์„ธํฌ๋‚ด ํ™œ์„ฑํ™”๋œ Ras๋ฅผ ์–ต์ œํ•˜๋Š” ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
KR102091195B1 (ko) ์„ธํฌ์งˆ ์นจํˆฌ ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
KR20180129514A (ko) ์„ธํฌ์งˆ ์นจํˆฌ ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
HK1240492A1 (en) Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
HK1240599A1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
EP3466970A1 (en) Cytosol-penetrating antibody and use thereof
KR20250093184A (ko) ๊ณ ํšจ์œจ ์„ธํฌ์งˆ ์นจํˆฌ ๋Šฅ์„ ๊ฐ–๋Š” ์„ธํฌ์งˆ ์นจํˆฌ ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
NZ749020B2 (en) Cytosol-penetrating antibody and use thereof
HK40008311A (en) Cytosol-penetrating antibody and use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHOD FOR INHIBITING INTRACELLULAR ACTIVATED RAS USING INTACT IMMUNOGLOBULIN-TYPE ANTIBODY HAVING CYTOSOL-PENETRATING ABILITY AND USE THEREOF

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired